Effective Asthma Management: Is It Time to Let the AIR out of SABA?

Autor: Kaplan A; Family Physician Airways Group of Canada, Edmonton T5X 4P8, Alberta, Canada., Mitchell PD; Cumming School of Medicine, University of Calgary, Calgary T2N 1N4, Alberta, Canada., Cave AJ; Department of Family Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton T6G 2R7, Alberta, Canada., Gagnon R; Association of Allergists and Immunologists of Québec, Montréal H5B 1G8, Québec, Canada., Foran V; Asthma Canada, Toronto M4S 2Z2, Ontario, Canada., Ellis AK; Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston K7L 3N6, Ontario, Canada.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2020 Mar 27; Vol. 9 (4). Date of Electronic Publication: 2020 Mar 27.
DOI: 10.3390/jcm9040921
Abstrakt: For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes. Instead, the more appropriate course is the use of a combined inhaled corticosteroid-fast acting beta agonist as a reliever. This paper discusses the issues associated with the use of SABA, the reasons that patients over-use SABA, difficulties that can be expected in overcoming SABA over-reliance in patients, and our evolving understanding of the use of "anti-inflammatory relievers" in our patients with asthma.
Competing Interests: The authors declare no conflict of interest. The funders had no role in developing the editorial content of this manuscript. A.K. is a member of an advisory board or speaker’s bureau for Astra Zeneca, Boerhringer-Ingelheim, Covis, Griffols, GSK, Pfizer, Purdue, Novartis, NovoNordisk, Sanofi, Talecris, and Trudel. P.D.M. reports receiving consulting fees from A.Z., GSK, Teva, and Sanofi, honorarium payments from A.Z., GSK, Teva, Sanofi, and Novartis, and unrestricted research grant support from A.Z., GSK, and Teva. A.J.C. has received research grants from The Lung Association, Grifols Canada, Alberta Innovates, and AstraZeneca and received honoraria from GSK, AstraZeneca, Sanofi, and Boerhinger-Ingelheim.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje